GRM1 and amyotrophic lateral sclerosis: Similarly, inhibition of glutamate release by riluzole, a drug approved by the US FDA for the treatment of amyotrophic lateral sclerosis (ALS), suppresses proliferation of GRM1-positive human tumor cells in vitro and tumor progression in vivo7,12,18,20.